• CDC News
  • Adult Immunization
  • Hepatology
  • Rare Disorders
  • Pediatric Immunization
  • Weight Management
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Kidney Disease
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Orthopedics
  • Obesity Medicine
  • Rheumatology
  • Technology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Serratia marcescens Pneumonia in an HIV-Infected Patient

Article

For 3 days, a 45-year-old woman with HIV infection who was noncompliant with her antiretroviral medications had cough, yellowish sputum, fever, and dyspnea. She denied hemoptysis, weight loss, or recent hospitalization. She had a long history of heavy smoking and alcohol and intravenous drug abuse.

For 3 days, a 45-year-old woman with HIV infection who was noncompliant with her antiretroviral medications had cough, yellowish sputum, fever, and dyspnea. She denied hemoptysis, weight loss, or recent hospitalization. She had a long history of heavy smoking and alcohol and intravenous drug abuse.

The patient had a high fever, tachycardia, tachypnea, and inspiratory rales in both lung fields but no evidence of hypoxia. White blood cell count was 23,500/μL, with 84% neutrophils. CD4+ cell count was 679/μL (well within the normal range). A chest radiograph revealed bibasilar patchy infiltrate (A).

Therapy with intravenous ceftriaxone and azithromycin was started for presumed community-acquired pneumonia, and the patient was isolated as a precaution. Her clinical condition did not improve with antibiotic and supportive treatment. No acidfast bacilli were isolated from sputum samples. A CT scan of the

chest showed extensive bilateral basilar pneumonitis (B). Multiple small cavities in both lungs were also noted. A subsequent bronchoscopy with lavage and bronchial washing isolated Serratia marcescens.

The patient responded well to intravenous imipenem. After 10 days, she was discharged.

The largest retrospective study of S marcescens infection in HIV patients (including 2398 cases) found documented S marcescens infection in only 0.71% of patients.1 All the affected patients were severely immunocompromised, with CD4+ cell counts of 70/μL or lower. An extensive literature review revealed that most of these infections (74% to 82%) were nosocomially acquired and were associated with a significantly high case-fatality rate (39% to 50%).2 Our case is unique because the infection was community-acquired and occurred in a patient with relatively preserved immune status.

References:

REFERENCES:


1.

Manfredi R, Nanetti A, Ferri M, Chiodo F. Clinical and microbiological surveyof Serratia marcescens infection during HIV disease.

Eur J Clin Microbiol InfectDis.

2000;19:248-253.

2.

Yu WL, Lin CW, Wang DY. Serratia marcescens bacteremia: clinical featuresand antimicrobial susceptibilities of the isolates.

J Microbiol Immunol Infect.

1998;31:171-179.

Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Related Content
© 2025 MJH Life Sciences

All rights reserved.